8-K: RespireRx Pharmaceuticals Secures $100,000 Loan and Issues Warrants to Board Member

RespireRx Pharmaceuticals has entered into a purchase agreement for a $100,000 loan and issued warrants to purchase 33,333,333 shares of common stock to Dariusz Nasiek, a member of the company's board of directors, and Sara Nasiek.

Summary

• RespireRx Pharmaceuticals Inc. entered into a Demand Promissory Note and Warrant Purchase Agreement on April 10, 2024.
• The company issued a demand promissory note for $100,000 and a warrant to purchase 33,333,333 shares of common stock.
• The loan accrues interest at 10% per annum, with principal and interest payable on demand.
• The warrant is exercisable for five years from the issue date at a price of $0.0015 per share.
• The lender is Dariusz Nasiek, a member of the Board of Directors, and Sara Nasiek, JTTEN.
• The proceeds from the loan will be used for research and development, general and administrative purposes, and working capital.

Sentiment

Score: 4

Explanation: The document indicates a necessary but potentially risky financing move. The high interest rate and potential dilution are concerning, but the company has secured needed funds. The related party transaction also adds a layer of caution.

Positives

• The company has secured additional funding of $100,000.
• The loan provides immediate access to capital.
• The warrant has the potential to bring in additional capital if exercised.

Negatives

• The loan carries a high interest rate of 10%.
• The loan is payable on demand, which could create financial uncertainty.
• The warrant issuance could dilute existing shareholders if exercised.
• The loan is secured by all of the company's assets, which could be risky.

Risks

• The demand nature of the loan could create financial instability if the lender demands repayment.
• The potential dilution of existing shares if the warrant is exercised could negatively impact the share price.
• The company's assets are pledged as collateral, which could be at risk if the company defaults on the loan.
• The transaction involves a related party, which could raise concerns about conflicts of interest.

Future Outlook

The company intends to use the proceeds from the loan for research and development, general and administrative purposes, and working capital.

Management Comments

• The company believes the price at which the Note and Warrant are being offered appropriately reflects economic realities under the company's current circumstances.
• The company acknowledges that there can be no assurances that the Note and Warrant are not worth substantially less than the price at which they are being sold.

Industry Context

This type of financing, involving a promissory note and warrants, is common for small pharmaceutical companies seeking to fund operations and research, especially when traditional financing options are limited. The involvement of a board member as a lender is not uncommon but requires careful scrutiny for potential conflicts of interest.

Comparison to Industry Standards

• The 10% interest rate on the promissory note is relatively high, which is not uncommon for small biotech companies with limited access to traditional financing.
• The warrant exercise price of $0.0015 per share is very low, suggesting a high level of risk and potential dilution for existing shareholders.
• Comparable companies in the biotech sector often use similar financing methods, including convertible notes and warrants, to raise capital.
• For example, companies like Aeterna Zentaris and Cassava Sciences have used similar financing structures in the past, often with warrants attached to debt instruments.
• The terms of the warrant, including the cashless exercise option, are fairly standard in these types of agreements.

Related Party Transactions

• The lender, Dariusz Nasiek, is a member of the Board of Directors of the company.

Stakeholder Impact

• Shareholders may experience dilution if the warrant is exercised.
• The company's employees may benefit from the additional funding for operations.
• Creditors may be impacted by the security interest granted to the lender.

Next Steps

• The company will use the funds for research and development, general and administrative purposes, and working capital.
• The lender may exercise the warrant at any time within the next five years.
• The company may need to seek additional financing in the future.

Key Dates

Keywords

promissory note, warrant, loan, capital, financing, RespireRx Pharmaceuticals, equity, debt, funding